B1054-100mg | Resiquimod (R-848) [144875-48-9] Clinisciences

Background

Resiquimod (R-848, S-27609) is a modifier of immune response [1].

Resiquimod (R-848, S-27609) is the analogue of imiquimod (R-837,S-26308). Resiquimod has been reported to dose-dependently induce some cytokines including IFN, TNF, IL-1β and IL-6 in human peripheral blood mononuclear (PBMCs). In addition, Resiquimod has been revealed to stimulate intracellular IL-1βincreased approximately 15%. The results have also been noted that both monocytes and B cells produced IFN in response to Resiquimod. Besides, Resiquimod has determined the induced increases in IFN-α, TNF, and IL-8 mRNA expression in PBMCs when compared with the untreated cell. Moreover, Resiquimod has been found to be an effective antiviral and antitumor agent in animal models [1].

References:
[1] Gibson SJ, Imbertson LM, Wagner TL, Testerman TL, Reiter MJ, Miller RL, Tomai MA.Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res. 1995 Jun; 15 (6): 537-45.

Product Citation

1. Hua Zhang, Wei-Lun Tang, et al. "Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy." J Control Release. 2020 Nov 13;S0168-3659(20)30662-3. PMID:33189786
2. Mohammed S, Vineetha NS, et al. "Examination of the role of sphingosine kinase 2 in a murine model of systemic lupus erythematosus." FASEB J. 2019 Jun;33(6):7061-7071. PMID:30840833
3. Qu S, Qin T, et al. "The effects of resiquimod in an ovalbumin-induced allergic rhinitis model." Int Immunopharmacol. 2018 Jun;59:233-242. PMID:29665497

Chemical Properties

Storage	Store at -20°C
M.Wt	314.38
Cas No.	144875-48-9
Formula	C17H22N4O2
Solubility	insoluble in H2O; ≥12.65 mg/mL in EtOH with ultrasonic; ≥15.85 mg/mL in DMSO
Chemical Name	1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol
SDF	Download SDF
Canonical SMILES	CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N
Shipping Condition	Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips	We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment [1]:
Cell lines	Peritoneal macrophages from wild-type and MyD88-deficient mice
Preparation method	The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting condition	100 nM
Applications	Unlike LPS-induced activation, which was MyD88-independent, Resiquimod-induced activation of NF-κB was completely dependent on MyD88. It was implied that Resiquimod activated macrophages via TLRs.
Animal experiment [1]:
Animal models	Wild-type, TLR7-deficient and MyD88-deficient mice
Dosage form	50 nmol; i.p.
Applications	In wild-type mice, Resiquimod (50 nmol, i.p.) increased serum concentrations of cytokines including IFN-alpha, TNF-alpha and IL-12. However, in TLR7-deficient and MyD88-deficient mice, there was not any increase in these cytokines.
Other notes	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References: [1] Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002 Feb; 3 (2): 196-200.